-

Thermo Fisher Scientific Opens Manufacturing Center of Excellence Site in North Carolina

New manufacturing facility in Mebane, N.C., site to significantly increase laboratory pipette production in the U.S.

WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific Inc., the world leader in serving science, today announced the grand opening of its innovative manufacturing center of excellence facility in Mebane, N.C. The new 375,000-square-foot carbon neutral site will be capable of producing at least 40 million laboratory pipette tips per week, helping to ensure that life-saving medicines and therapies continue to be developed and produced in the U.S. for decades to come.

“As a global leader in life sciences manufacturing, we’re proud to serve as a growth engine for the American economy and provide our customers with a strong and agile supply chain that enables them to advance human health,” said Erica Hirsch, president, laboratory chemicals, Thermo Fisher Scientific. “The opening of our Mebane site is a testament to our larger strategy to strengthen our manufacturing capabilities in the U.S. and support continued innovation and expanded growth in North Carolina, building on the strong foundation we’ve already established in this state.”

Pipette tips are critical tools for research and diagnostics, enabling precise liquid handling in high-volume applications such as disease studies and diagnostic testing. Thermo Fisher manufactures its tips with high-quality materials and strict quality controls to ensure accuracy, reduce contamination, and deliver consistent performance. The new Mebane site is built for efficiency, with advanced automation that produces 96 tips every 12 seconds and 5,000 finished assemblies per hour. Designed for seamless operations, it also features automated packaging and shipping to meet growing customer demand.

“Thermo Fisher Scientific’s new facility strengthens North Carolina’s leadership in the biotech sector and strengthens our domestic supply chain,” said Governor Josh Stein. “I am proud to welcome this global company to Mebane as it expands its North Carolina presence with 100 good-paying jobs.”

The new Mebane site has already hired 40 people and is expected to add 50 jobs in manufacturing, engineering and business operations. Thermo Fisher currently employs approximately 7,800 colleagues across 13 sites in N.C., including a center of excellence for laboratory equipment in Asheville, three life sciences [and] manufacturing sites in Durham, pharmaceutical manufacturing sites in Greenville and High Point, and a Raleigh distribution center.

The site results from a $192.5 million contract, in coordination with the U.S. Department of Health and Human Services (HHS) and the U.S. Department of Defense (DoD), awarded in 2021. In addition to investing $1 billion in R&D in the U.S. annually, Thermo Fisher has more than doubled in size in the U.S. since 2017, now employing more than 50,000 people in the U.S. today.

About Thermo Fisher Scientific
Thermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue over $40 billion. Our Mission is to enable our customers to make the world healthier, cleaner and safer. Whether our customers are accelerating life sciences research, solving complex analytical challenges, increasing productivity in their laboratories, improving patient health through diagnostics or the development and manufacture of life-changing therapies, we are here to support them. Our global team delivers an unrivaled combination of innovative technologies, purchasing convenience and pharmaceutical services through our industry-leading brands, including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services, Patheon and PPD. For more information, please visit www.thermofisher.com.

Contacts

Media Contact Information:
Angela Christoforos
achristoforos@greenoughagency.com

Abbie Henderson
Abbie.Henderson@thermofisher.com

Thermo Fisher

NYSE:TMO
Details
Headquarters: Waltham, Massachusetts
CEO: Marc N. Casper
Employees: 100,000
Organization: PUB
Revenues: $40 Billion (2021)

Release Versions

Contacts

Media Contact Information:
Angela Christoforos
achristoforos@greenoughagency.com

Abbie Henderson
Abbie.Henderson@thermofisher.com

More News From Thermo Fisher

Thermo Fisher Scientific Deepens Investment in Asia’s Biopharma Ecosystem with Expansion of Bioprocess Design Centers

WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific Inc., the world leader in serving science, today announced an expansion of its bioprocessing capabilities across Asia, reinforcing its commitment to supporting the region’s rapidly growing biopharmaceutical industry. The company is introducing a new Bioprocess Design Center in Hyderabad, India, and has expanded its existing Bioprocess Design Centers in Incheon, Korea and Singapore, further strengthening a strategic regional network desig...

Thermo Fisher Scientific Prices Offering of Euro-Denominated Senior Notes

WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific Inc. (NYSE: TMO) (“Thermo Fisher”) announced today that it has priced an offering of €2.1 billion aggregate principal amount (the “Offering”) of the following euro-denominated notes, which will be issued by Thermo Fisher Scientific (Finance I) B.V., its indirect, wholly-owned finance subsidiary: €1,000,000,000 aggregate principal amount of its floating rate senior notes due 2027 (the “floating rate notes”) at the issue price of 100.000%...

Thermo Fisher Scientific’s Oncomine Dx Target Test Receives FDA Approval as a Companion Diagnostic to Identify Patients Eligible for Newest Targeted Therapy for Non-Small Cell Lung Cancer

CARLSBAD, Calif.--(BUSINESS WIRE)--Thermo Fisher Scientific, the world leader in serving science, has received approval from the U.S. Food and Drug Administration (FDA) for its Ion Torrent™ Oncomine™ Dx Target Test as a companion diagnostic (CDx) to identify patients who may be eligible for treatment with HYRNUO™ (sevabertinib), a new HER2-directed therapy developed and commercialized by Bayer. The test enables clinicians and pathologists to identify non-small cell lung cancer (NSCLC) tumors wi...
Back to Newsroom